selegiline with citalopram

[Guest guest]

,

I don't know if you are/were taking Prozac because you need to take an SSRI.

But if so, and if you want to take an SSRI with selegiline (Deprenyl) but

are concerned about the risks of interaction, then you might want to ask

yourself or your doctor about the possibility of taking citalopram (Celexa)

instead of Prozac.

Celexa is an SSRI that might work as well as Prozac and which has been

tested with selegiline. In this test described below there was no apparent

interaction between the drugs.

Title

Lack of adverse interactions between concomitantly administered selegiline

and citalopram.

Author

Laine K ; Anttila M ; Heinonen E ; Helminen A ; Huupponen R ; M¨aki-Ikola O

; Reinikainen K ; Scheinin M

Address

Department of Pharmacology and Clinical Pharmacology, University of Turku,

Finland.

Source

Clin Neuropharmacol, 20(5):419-33 1997 Oct

Abstract

We have evaluated the risk for pharmacokinetic and/or pharmacodynamic

interactions of concomitantly administered selegiline, a selective monoamine

oxidase type B inhibitor, and citalopram, a widely used selective serotonin

uptake inhibitor antidepressant. Two parallel groups of healthy volunteers

received 20 mg of citalopram (n = 12) or placebo (n = 6) once daily for 10

days in a randomized, double-blind fashion, followed by concomitant

selegiline 10 mg once daily for 4 days. The safety of this drug combination

was assessed by measurements of blood pressure, heart rate, body

temperature, and inquiries for adverse events. Blood samples were taken for

the analysis of serum concentrations of both study drugs and their

metabolites and plasma prolactin, adrenaline, noradrenaline, and

3,4-dihydroxyphenylglycol (DHPG); urinary excretion of serotonin and

5-hydroxyindoleacetic acid (5-HIAA) were assessed. After a 5-week washout,

the 12 subjects who took citalopram in the first part of the study received

10 mg of selegiline once daily for 4 days to compare the pharmacokinetics of

selegiline with and without concomitant citalopram. The safety analysis

showed no significant differences in vital signs or the frequency of adverse

events between the study groups. Plasma prolactin concentrations were

increased by 40% after 10 days' treatment with citalopram (p = 0.03); this

was not potentiated by concomitantly administered selegiline. The comparison

of plasma concentrations of noradrenaline, adrenaline, and DHPG and the

amount of serotonin and 5-HIAA excreted into urine between the study groups

indicated no signs of subclinical pharmacodynamic interaction between

selegiline and citalopram. The relative bioavailability of selegiline was

slightly reduced (by 29%; p = 0.008) when citalopram was coadministered

compared with selegiline alone. However, no indication of a pharmacokinetic

interaction was found in the analysis of serum concentrations of the three

main metabolites of selegiline. The pharmacokinetics of citalopram remained

unaffected by concomitant selegiline. The present results indicate lack of

clinically relevant pharmacodynamic or pharmacokinetic interactions between

selegiline and citalopram.

Language

Eng

Unique Identifier

97472559

-gts